Monika Lukoseviciute

Publications
CV
Public outreach and news

Articles

Article: ONCOLOGY REPORTS. 2023;49(6):125

Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma.

Lukoseviciute M; Theodosopoulou A; Holzhauser S; Dalianis T; Kostopoulou ON
Article: CANCERS. 2022;15(1):93

Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited.

Byskata K; Lukoseviciute M; Tuti F; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Article: VIRUSES-BASEL. 2022;14(7):1372

Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors.

Kostopoulou ON; Zupancic M; Pont M; Papin E; Lukoseviciute M; Mikelarena BA; Holzhauser S; Dalianis T
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2021;58(2):211-225

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.

Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickström M; Kostopoulou ON; Dalianis T
Article: FRONTIERS IN ONCOLOGY. 2021;11:748657

Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines.

Lukoseviciute M; Maier H; Poulou-Sidiropoulou E; Rosendahl E; Holzhauser S; Dalianis T; Kostopoulou ON
Article: ANTICANCER RESEARCH. 2020;40(1):53-66

Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines.

Holzhauser S; Lukoseviciute M; Andonova T; Ursu RG; Dalianis T; Wickström M; Kostopoulou ON

Articles

Employments

Degrees and Education

News from KI

Events from KI